Annual Financial Report

By Investing Today

March 6, 2025

Company Announcement – Euronext Dublin
No. 01/2025

Copenhagen, 6 March 2025

STG A/S – Annual Report 2024

On 6 March 2025, Scandinavian Tobacco Group A/S published its Annual Report 2024 and its consolidated interim report for 1 January – 31 December 2024.

The Annual Report and company announcement of Scandinavian Tobacco Group A/S relating to the published reports are available at: https://www.st-group.com/investor/.

For further information, please contact:

Torben Sand, Director of IR & Communication, phone +45 5084 7222, [email protected].
Eliza Dabbagh, IR & Communications, phone +45 5080 7619, [email protected].

Attachments

STG Annual Report 2024
STG Group Ireland – Company Announcement no 1 2025

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

Scandinavian Tobacco Group A/S: Annual Report 2024

SANOMA CORPORATION: ACQUISITION OF OWN SHARES 06 March 2025

Annual Financial Report

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Changes in the Supervisory Board and Management Board of subsidiary

Topics

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Changes in the Supervisory Board and Management Board of subsidiary

Holding(s) in Company

C3is Inc. announces the date for the release of the fourth quarter and full year 2024 financial and operating results

Rail Vision Receives Nasdaq Notification Regarding Minimum Bid Requirements

Related Articles

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Changes in the Supervisory Board and Management Board of subsidiary

Company

Headlines

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Kaldalón hf.: Annual General Meeting 3 April 2025

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Newsletter